Nektar Therapeutics (NKTR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.27B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nektar Therapeutics (NKTR) Competitors
The companies most similar to Nektar Therapeutics are Nuvation Bio (NUVB), Nuvectis Pharma (NVCT) and Structure Therapeutics Inc. American Depositary Shares (GPCR). By market cap, Nektar Therapeutics ranks 8th of the 13 companies on this page; Vera Therapeutics (VERA) is the largest at $2.03B.
Peer Comparison
NKTR's revenue growth of -20.4% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Nektar Therapeutics (NKTR) | $1.27B | N/A | 23.9x | 0.0% | N/A | -20.4% | 0.00% |
| Nuvation Bio Inc (NUVB) | $1.41B | N/A | 6.7x | -67.4% | -18.7% | 242.6% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Nurix Therapeutics Inc (NRIX) | $1.69B | 6.4x | 2.3x | 42.0% | N/A | 8426.0% | 0.00% |
| Immatics NV (IMTX) | $972.99M | N/A | 17.7x | 0.0% | N/A | 33.5% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Ultragenyx (RARE) | $1.64B | N/A | 2.2x | -71.8% | N/A | 8.1% | 0.00% |
| Novavax Inc (NVAX) | $1.41B | N/A | 3.2x | -18.6% | -66.6% | -3.0% | 0.00% |
| Vera Therapeutics Inc (VERA) | $2.03B | N/A | 189.3x | 0.0% | -83.0% | 0.0% | 0.00% |
| Inhibrx Biosciences, Inc. (INBX) | $1.23B | N/A | 610.4x | 0.0% | -66.0% | -100.0% | 0.00% |
| Septerna, Inc. Common Stock (SEPN) | $2.03B | N/A | 20.3x | -61.3% | N/A | -12.2% | 0.00% |
| Alto Neuroscience, Inc. (ANRO) | $1.18B | N/A | N/A | 0.0% | -23.5% | 0.0% | 0.00% |
| Peer median | $1.41B | 50.8x | 8.4x | 0.0% | -66.0% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Nektar Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Nuvation Bio Inc (NUVB) | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. | NUVB competitors |
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Nurix Therapeutics Inc (NRIX) | Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development... | NRIX competitors |
| Immatics NV (IMTX) | Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies... | IMTX competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Ultragenyx (RARE) | Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development... | RARE competitors |
| Novavax Inc (NVAX) | Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases... | NVAX competitors |
| Vera Therapeutics Inc (VERA) | Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases... | VERA competitors |
| Inhibrx Biosciences, Inc. (INBX) | Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. | INBX competitors |
| Septerna, Inc. Common Stock (SEPN) | Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform. | SEPN competitors |
| Alto Neuroscience, Inc. (ANRO) | Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. | ANRO competitors |
Frequently Asked Questions About NKTR
Who are Nektar Therapeutics' main competitors?
The companies most similar to Nektar Therapeutics include Nuvation Bio (NUVB), Nuvectis Pharma (NVCT), Structure Therapeutics Inc. American Depositary Shares (GPCR), Nurix Therapeutics (NRIX) and Immatics NV (IMTX), listed from the closest match.
Who is Nektar Therapeutics' biggest competitor?
Vera Therapeutics (VERA) is the largest of the similar companies at $2.03B; Nuvation Bio (NUVB) is the closest match by business profile, size, sector and industry.
How does NKTR stock compare with its competitors?
NKTR's P/S is 23.9x against a peer median of 8.4x; its net margin is 0.0% against a peer median of 0.0%.
Which of Nektar Therapeutics' competitors pays a higher dividend?
Nektar Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Nektar Therapeutics bigger than its competitors?
No. Nektar Therapeutics is 8th by market cap among the 13 companies on this page; the largest is Vera Therapeutics (VERA) at $2.03B.
NKTR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors